Pediatric CML Publications
Genomic variant profiling in blast-phase paediatric chronic myeloid leukemia: Predisposing and driving alterations
Behrens YL et al. Br J Haematol, May 2025 (epub ahead of print)
open access publication
Allogeneic hematopoietic stem cell transplantation in pediatric and young adult patients with chronic myeloid leukemia in tyrosine kinase inhibitor era: A study of the Korean Blood and Marrow Transplantation Registry
Ju HY et al. Cancer Res Treat, May 2025 (epub ahead of print)
open access publication
NAMPT-mediated deacetylation of HCLS1 protein promoted clonogenic growth of pediatric CML cells
Samareh B et al. Exp Hematol, May 2025 (epub ahead of print)
Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.
Michalowski, MB et al. Case Reports in Oncological Medicine, March 2025
open access publication
Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric chronic myeloid leukemia expert panel recommendations
Millot F et al. Leukemia, March 2025 (epub ahead of print)
Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Data from a real-world setting
Suttorp M et al. Br J Haematol, March 2025 (epub ahead of print)
open access publication
Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era
Yoshikawa T et al. Int J Hematol, March 2025 (epub ahead of print)
open access publication
Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
Seiser E et al. J Mol Diagn, January 2025 (epub ahead of print)
Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric low middle-income country (LMIC) patients
Bukhari SI et al. Cancer Invest, January 2025 (epub ahead of print)
Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Shima H et al. Leukemia, December 2024 (epub ahead of print)
Treatment-free remissions in children with chronic myeloid leukemia (CML): A prospective study from the Tata Memorial Hospital (TMA) Pediatric CML (pCML) cohort
Roy Moulik N et al. Am J Hematol, November 2024 (epub ahead of print)
open access publication
Clinical characteristics and outcomes of CML in adolescents and young adults
Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024
A high proportion of germline variants in pediatric chronic myeloid leukemia in pediatric chronic myeloid leukemia
Krumbhold M et al. Mol Cancer, Sept 2024
open access publication
CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast crisis
Kramp LJ et al. Ann Hematol, Sept 2024 (epub ahead of print)
open access publication
Low-level BCR::ABL1 transcript at diagnosis in childhood leukemia: A 10-year single institution study
Cain LE et al. Genes Chromosomes Cancer, Sept 2024
Chronic myeloid leukemia in adolescents and young adults: Clinicopathological variables and outcomes
Abdulla MA et al. Oncology, July 2024 (epub ahead of print)
open access publication
Impact of tyrosine kinase inhibitors (TKIs) on growth in children and adolescents with chronic myeloid leukemia: A systematic review
Katsarou D et al. Curr Pharm Des, July 2024 (epub ahead of print)
Childhood chronic myeloid leukemia treatment (PDQ): Health Professional Version - Review
PDQ Pediatric Treatment Editorial Board June 2024
In: PDQ Cancer Information Summaries (Internet) Bethesada (MD) National Cancer Institute (US); 2002-.
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with CML: A prospective multicentre trial of the I-BFM Study Group
Pichler H et al. Br J Haematol, May 2024 (epub ahead of print)
open access publication
Priapism and chronic myeloid leukemia in an adolescent. Rare debut presentation. A case report.
Romero-Guerra AL et al. Arch Argent Pediatr, April 2024
open access publication
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia
Behrens YL et al. Haematologica, March 2024
open access publication
Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED Cohort
Stiehler S et al. Haematologica, March 2024 (epub ahead of print)
open access publication
Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patient with chronic myeloid leukemia
Abdallah AM et al. Leuk Lymphoma, March 2024 (epub ahead of print)
Chronic spontaneous urticarial as the presenting factor in a paediatric case of chronic myeloid leukemia
Sutton KM et al. Pediatr Blood Cancer, March 2024
Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: Results from the Phase I part of Study ITCC054/COG AMML1921
Brivio E et al. J Clin Oncol, March 2024
open access publication
A 3-year old with chronic myeloid leukemia
Coty-Fatall Z & Richardson A. Blood, February 2024
Challenges in management of pediatric chronic myeloid leukemia (pCML) in the low- and middle income countries (LMICs’): Insights from an International CML Foundation (iCMLf) Multi National Study
Roy Moulik N et al. Pediatr Hematol Oncol, January 2024 (epub ahead of print)
Pediatric chronic myeloid leukemia P190 variant with IgA vasculitis: Rare association – case report
Shah K et al. Pediatr Blood Cancer, January 2024
Bosutinib: Pediatric first approval - Review
Hoy SM. Paediatr Drugs, December 2023 (epub ahead of print)
Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia - Review
Toker M et al. Pediatr Dermatol, December 2023 (epub ahead of print)
Treatment and follow-up of children with chronic myeloid leukemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era – Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort
Roy Moulik N et al. Br J Haematol, December 2023 (epub ahead of print)
Chronic myeloid leukemia (CML) in children and adolescents – Clinicopathological findings
Nevejan L et al. Eur J Haematol, November 2023 (epub ahead of print)
Physiologically based pharmacokinetics modelling of nilotinib for drug-drug interactions, pediatric patients, and pregnancy and lactation
Liu XI et al. J Clin Pharmacol, November 2023 (epub ahead of print)
Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia
Volz C et al. Sci Rep, October 2023
open access publication
Somatic variant profiling in chronic phase pediatric CML
Behrens YL et al. Haematologica, Sept 2023 (epub ahead of print)
open access publication
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Hijiya N et al. Blood Adv, Sept 2023 (epub ahead of print)
Priapism at Diagnosis of Pediatric Chronic Myeloid Leukemia: Data Derived from a Large Cohort of Children and Teenagers and a Narrative Review on Priapism Management
Suttorp M et al. J Clin Med, July 2023
open access publication
Chronic myeloid leukemia in children and adolescents - Review
Gotesman M et al. Adv Pediatr, August 2023
Effect of imatinib mesylate on growth in pediatric CML: A systematic review and meta-analysis
Gupta P et al. J Pediatr Hematol Oncol, July 2023
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults
Mersin S et al. Expert Opin Pharmacother, July 2023 (epub ahead of print)
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase CML in the tyrosine kinase inhibitor era
Ishida H et al. Am J Hematol, May 2023 (epub ahed of print)
Pediatric chronic myeloid leukemia in myeloid blast crisis
Dey B and Dutta A. Autpos Case Rep, April 2023
open access publication
Recent progress in the management of pediatric chronic myeloid leukemia
Shima H & Shimada H. Int J Hematol, February 2023
open access publication
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations – Review
Sembill S et al. Leukemia, January 2023 (epub ahead of print) – open access publication
Impact of tyrosine kinase inhibitors applied for first-line chronic myeloid leukemia treatment on platelet function in whole blood of healthy volunteers in vitro
Eckart F et al. Hamostaseologie, January 2023 (epub ahead of print)
Children with chronic myeloid leukemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan
Liu HC et al. Br J Cancer, January 2023 (epub ahead of print)
Relative bioavailability and food effect of asciminib pediatric mini-tablet formulation compared to the reference tablet formulation in healthy adult participants
Hoch M et al. Clin Pharmacol Drug Dev, January 2023 (epub ahead of print)
open access publication
Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia
Schleicher O et al. Front Oncol. September 2022
open access publication
Recent progress in the management of pediatric chronic myeloid leukemia – Review
Shima H and Shimada H. Int J Hematol, December 2022 (epub ahead of print)
Alterations in cellular metabolism after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
Li C et al. Front Oncol, December 2022
open access publication
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Nishiyama-Fujita Y et al. Ann Med, December 2022
open access publication
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course
Delehaye F et al. Ann Hematol, November 2022 (epub ahead of print)
Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment
Karadas N et al. Int J Hematol, November 2022 (epub ahead of print)
Outcome of pediatrc chronic myeloid leukemia with management focusing on gene transcript levels
Al-Ghemlas I et al. Int J Pediatr Adolesc Med, September 2022 (epub ahead of print)
Dasatinib-related pleural effusion anad lymphocytosis rates are different between adult and pediatric patients with Philadelphina chromosome-positive leukemias: are age and comorbidities only to blame?
Kiliçasian NA et al. Expert Rev Respir Med, September 2022 (epub ahead of print)
Secondary pseudotumor cerebri syndrome in a child with chronic myeloid leukemia: Report of a case and review of previous cases
Rasmussen AH et al. Pediatr Blood Cancer, September 2022 (epub ahead of print)
Management of CML in children and young adults - Review
Ford M et al. Curr Hematol Malig Res, August 2022 (epub ahead of print)
open access publication
Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
Kim Y et al. Front Pediatr, Jul 2022
open access publication
Ponatinib in pediatric patients with Philadelphina chromosome-positive leukemia: a retrospective survey of the Japan Children’s Cancer Group
Kodama Y et al. Int J Hematol, July 2022
Sensoineural hearing loss in juvenile CML: A Rare Case Report in Surabaya, Indonesia
Syamsuddin IK and Notopuro PB. Int Med Case Rep J, July 2022
open access publication
Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection
Vuorenoja S et al. Cancer Rep (Hoboken), July 2022 (epub ahead of print)
open access publication
Outcome prediction of chronic myeloid leukemia (CML) in children
Leung WY et al. Ann Hematol, June 2022 (epub ahead of print)
Pediatric chronic myelogenous leukemia in T-lineage blast crisis: A reminder in relevance
Patel SA and Beck JC. J Pediatr Hematol Oncol, April 2022
Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia
Dong EE et al. Pediatr Blood Cancer, May 2022 (epub ahead of print)
Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
Shima H et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)
Prognostic factors for outcomes of allogeneic HSCT for children and adolescents/young adults with CML in the TKI era
Shimada H et al. Transplant Cell Ther, April 2022 (epub ahead of print)
Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment
Uchida E et al. Pediatr Blood Cancer, April 2022 (epub ahead of print)
Therapeutic leukapharesis in pediatric leukemia: Utilization trend and early outcomes in a US Nationwide Cohort
Takahashi T et cl. J Pediatr Hematol Oncol, March 2022
Design and stability of pediatric oral formulation of imatinib
Hinterlang M et al. J Oncol Pharm Pract, March 2022
Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML
Smith SM et al. Pediatr Hematol Oncol, December 2021 (epub ahead of print)
Comparison of the transcriptomic signature in pediatric and adult CML
Youn M et al. Cancers(Basel), December 2021
open access publication
Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase
Lee JW et al. Blood Res, November 2021
Seven year long follow-up of patient with childhood chronic myeloid leukemia postsecond haploidentical stem cell transplant
Sachdev M et al. J Pediatr Hematol Oncol, November 2021
Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis and acute upper gastrointestinal haemorrhage: A case report
Zhang Y et al. J Pediatr Hematol Oncol, October 2021
Chronic myeloid leukemia in children: immune functions and vaccinations
Suttorp M et al. J Clin Med, September 2021
open access publication
Discontinuation of imatinib in children with chronic myeloid leukemia: A study from the International Registry of childhood CML
Millot F et al. Cancers(Basel), August 2021
open access publication
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety
Hijiya N et al. Blood Adv, July 2021 (epub ahead of print)
open access publication
Adolescents experienced more treatment failure than children with CML receiving imatinib as frontline therapy: a retrospective multicentre study
Dou X et al. Ann Hematol, June 2021 (epub ahead of print)
Sudden blast phase in paediatric chronic myeloid leukemia-chronic phase with abnormal blasts detected by flow cytometry at diagnosis. Can it be considered a warning sign?
Vijayasekharan K et al. Cytometry B Clin Cytom, May 2021
Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children
Phillips LN and Hijiya N. Paediatr Drug, April 2021 (epub ahead of print)
Paediatric chronic myeloid leukemia presenting in de novo or secondary blast phase – a comparison of clinical and genetic characteristics
Sembill S et al. Br J Haematol, March 2021 (epub ahead of print)
open access publication
Chronic myelogenous leukemia in childhood
Smith SM et al. Curr Oncol Rep, March 2021
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: Single-Center experience from China
Cai Y et al. Int J Hematol, January 2021 (epub ahead of print)
Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia
Suttorp M et al. Cancers(Basel), February 2021
open access publication
Successful haploidentical stem cell transplant with posttransplant cyclophosphamide for isolated central nervous system blast crisis in a child with CML
Chatterjee G et al. J Pediatr Hematol Oncol, January 2021
Factors and outcomes of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry
Meral Günes A et al. Pediatr Blood Cancer, October 2020
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukemia treated with imatinib: A report from the I-CML-Ped Study
Meyran D et al. Eur J Cancer, August 2020 (epub ahead of print)
A case of childhood blastic phase chronic myeloid leukemia with minor BCR-ABL
Yamanaka J et al. J Pediatr Hematol Oncol, August 2020
Pediatric chronic myeloid leukemia with myeloid blast crisis and complex karyotype at presentation
Sazawal S et al. Indian J Cancer, July – Sept 2020
open access publication
Outcomes of children with chronic myeloid leukemia: A population-based cohort study
Egan G et al. Pediatr Blood Cancer, July 2020
BCR-ABL tyrosine kinase inhibitors in the treatment of pediatric CML
Carofiglio F et al. Int J Mol Sci, June 2020
open access publication
Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation and the effects on growth in a child with CML: not always a short story
Triche L et al. Pediatr Hematol Oncol, August 2020
open access publication
Ponatinib in childhood Philadelphia chromosome-positive leukemias: an International registry of childhood chronic myeloid leukemia study
Millot F et al. Eur J Cancer, July 2020
Imatinib-induced hypogammaglobulinemia in children and adolescents with chronic myeloid leukemia
Totadri S et al. Pediatr Hematol Onco, May 2020 (epub ahead of print)
Vaccination with live attenuated vaccines in four children with chronic myeloid leukemia while on imatinib treatment
Bettoni da Cunha-Riehm C et al. Front Immunol, April 2020
open access publication
Experience with ponatinib in paediatric patients with leukaemia
Rossoff J et al. Br J Hematol, January 2020 (epub ahead of print)
Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimes for imatinib and potential drug interactions in paediatrics
Adiwidaja J et al. Front Pharmacol, January 2020
open access publication
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia
Hijiya N et al. Clin Cancer Res, February 2020
open access publication
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukemia
Giona F et al. Br J Hematol, February 2020 (epub ahead of print)
Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single-center experience
Hafez HA et al. Pediatr Transplant, February 2020
Discontinuation of imatinib in a child with chronic myeloid leukemia
Jeyaram P et al. Pediatr Hematol Oncol, January 2020
Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukemia in children
Knöfler R et al. Br J Haematol, October 2019 (epub ahead of print)
Acquired neuro-secretory defect in growth hormone secretion due to imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia
Walia R et al. Pediatr Hematol Oncol, November 2019 (epub ahead of print)
Discontinuation of tyrosine kinase inhibitor in children with chronic myeloid leukemia (JPLSG STKI-14 study)
Shima H et al. Blood, November 2019
Successful haploidentical stem cell transplant with post-transplant cyclophosphamide for isolated central nervous system blast crisis in a child with chronic myeloid leukemia
Chatterjee G et al. J Pediatr Hematol Oncol, November 2019 (epub ahead of print)
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia
Hijiya N et al. Blood, December 2019
Pediatric chronic myeloid leukemia presenting in a mixed phenotypic blast crisis: A rare occurrence
Bhattarcharya J et al. Turk H Haematol, August 2019
The small problem when treating childhood chronic myeloid leukemia
Suttorp M et al. Pediatr Hematol Oncol, July 2019 (epub ahead of print)
Effect of imatinib on growth in children with chronic myeloid leukemia
Boddu D et al. Pediatr Hematol Oncol, July 2019 (epub ahead of print)
Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia
Liu Y et al. AMB Express, July 2019
Large amplicon droplet PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia
Krumbholz M et al. J Cell Mol Med, June 2019 (epub ahead of print)
Favourable outcome of de novo advanced phases of childhood chronic myeloid leukemia
Millot F et al. Eur J Cancer, May 2019 (epub ahead of print)
How I treat chronic myeloid leukemia in children and adolescents
Hijiya N et al. Blood, March 2019 (epub ahead of print)
Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED Study
de Bruijn CMA et al. Br J Hematol, March 2019 (epub ahead of print)
Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia
McCafferty EH et al. Paediatric Drugs, November 2018 (epub ahead of print)
Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience
Giona F et al. Acta Haematol, September 2018 (epub ahead of print)
Generic formulations of imatinib for treatment of Philadelphia chromosome–positive leukemia in pediatric patients
Suttorp M et al. Pediatr Blood Cancer, August 2018 (epub ahead of print)
Temporal trends in the proportion of “cure” in children, adolescents, and young adults diagnosed with chronic myeloid leukemia in England: A population-based study
Drozdov D et al. Pediatr Blood Cancer, August 2018 (epub ahead of print)
Dasatinib-Induced Hypopigmentation in Pediatric Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature
Alharbi B et al. Case Report Dermatol Med, July 2018
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial
Suttorp M et al. Leukemia, June 2018
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia
Ernst T et al. Leukemia, June 2018
Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia
Boklan JL et al. J Pediatr Hematol Oncol, August 2018
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib (2)
Giona F. et al. Br J Hematol, March 2018
open access publication
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Gore L. M et al. J Clin Oncol, March 2018
Pharmacology and pharmacokinetics of imatinib in pediatric patients
Suttorp M et al. Expert Rev Clin Pharmacol, November 2017
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
Millot F et al. Haematologica, August 2017
open access publication
The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia
Samis J et al. Pediatr Blood Cancer, July 2017
Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents
Millot F et al. Cancer, May 2017
open access publication
Death Within 1 Month of Diagnosis in Childhood Cancer: An Analysis of Risk Factors and Scope of the Problem
Green A et al. J Clin Oncol, March 2017
Flow cytometric analysis as an additional predictive tool of treatment response in children with chronic-phase chronic myeloid leukemia treated with imatinib
Shima H et al. Pediatr Blood Cancer, February 2017
Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis
Hussein K et al. Leukemia, February 2017
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib
Giona F. et al. Br J Haematol, December 2016
open access publication
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy
Proschmann R. et al. Haematologica, November 2016
open access publication
Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America
Karalexi MA et al. Eur J Cancer, November 2016
Impact of age on the survival of pediatric leukemia: an analysis of 15083 children in the SEER database
Wang Y et al. Oncotarget, August 2016
open access publication
Pediatric chronic myeloid leukemia with inv(3)(q21q26.2) and T lymphoblastic transformation: a case report
Lewen M et al. Biomark Res, July 2016
open access publication
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib
Mashan A et al. Pediatr Blood Cancer, December 2016 (epub ahead of print)
Outcomes Following Bone Marrow Transplantation in Children With Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors
Shulman DS et al. J Pediatr Hematol, November 2016 (epub ahead of print)
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia
Samis J et al. Pediatr Blood Cancer, April 2016 (epub ahead of print)
Optimal management for pediatric chronic myeloid leukemia
Tanzizawe A. Pediatrics International, March 2016
Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience
Giona F et al. Br J Haematol, February 2016 (epub ahead of print)
Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia
Menon NN et al. Ann Hematol, January 2016 (epub ahead of print)
Pediatric chronic myeloid leukemia is a unique disease that requires a different approach
Hijiya N. et al. Blood, October 2015 (epub ahead of print)
open access publication
Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group
Kurosawa H et al. Pediatr Blood Cancer. October 2015 (epub ahead of print)
Atypical chronic myeloid leukemia in two pediatric patients
Freedman JL et al. Pediatr Blood Cancer, August 2015
Long-term results of high-dose imatinib in children and adolescents with CML in chronic phase: The Italian experience
Giona F et al. Br J Haematol, April 2015 (epub ahead of print)
Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D et al. Ann Hematol, April 2015
Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions
Hijija N et al. Pediatr Clin North Am, February 2015
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia
Millot F et al. Eur J Cancer, October 2014
Differences among young adults, adults and elderly chronic myeloid leukemia patients
Castagnetti F et al. Ann. Oncol, October 2014
open access publication
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years
Fuente et al. Br J Haematology, July 2014
open access publication
Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia
Moser et al. Pediatr Blood Cancer, May 2014
Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007
Ferrara JL. Biol Blood Marrow Transplant, Feb. 2014
open access publication
Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase
Millot et al. Pediatr Blood Cancer, February 2014
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty
Giona et al. Haematologica, September 2012
open access publication
How I treat childhood CML
Andolina et al. Blood, December 2011
open access publication
Imatinib Has Adverse Effect on Growth in Children With Chronic Myeloid Leukemia
Bansal et al. Pediatr Blood Cancer, November 2011
Imatinib Is Effective in Children With Previously Untreated CML in Early Chronic Phase: Results of the French National Phase IV Trial
Millot et al. J Clin Oncology, June 2011
Pediatric phase I trial and pharmacokinetic study of dasatinib
Aplenc et al. J Clin Oncology, November 2011
open access publication
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with CML
Shima et al. J of Pediatrics, May 2011
Controversies in treatment of CML in children and adolescents: TKI versus BMT?
Suttorp M et al, Biology of Blood and Marrow Transplantation, January 2011
open access publication